Otros idiomas Grand Pharmaceutical Group Limited

Acciones

512 BMG210A71016

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:17 07/05/2024			Varia. Cinco días.	Varia. 1 de enero.
4,61 ^HKD	+2,90 %		+6,22 %	+12,71 %

29/04	El beneficio de Grand Pharmaceutical baja un 10% en 2023 a pesar de un aumento de los ingresos del 10	MT
27/03	Grand Pharmaceutical Group Limited firma un acuerdo de cooperación estratégica para la introducción de productos con LianBio Development (HK) Limited y Tarsus Pharmaceuticals, Inc.	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	29/04
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	27/03
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug	25/03
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors	24/03
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024	19/03
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication	08/03
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial	08/03
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884	07/03
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China	08/02
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator	24/01
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan	16/01
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops	27/12
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA	27/12
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million	22/12
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan	18/12
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan	13/12
Grand Pharmaceutical Unit Enrolls, Doses 1st Patient in Sepsis Drug Phase 2 Trial	27/11
Grand Pharma Gets China's Nod for Phase 1 Clinical Trial for Tumor Vaccine	03/11
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01	02/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Grand Pharmaceutical Group Limited

Acciones

512

BMG210A71016

Otros idiomas

Filtros